Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues

A combination of anti–CTLA-4 plus anti–PD-1/PD-L1 is the most effective cancer immunotherapy but causes high incidence of immune-related adverse events (irAEs). Here we report that targeting of HIF-1α suppressed PD-L1 expression on tumor cells and tumor-infiltrating myeloid cells, but unexpectedly i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Christopher M., Liu, Yan, Liu, Mingyue, Du, Xuexiang, Devenport, Martin, Zheng, Pan, Liu, Yang, Wang, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057613/
https://www.ncbi.nlm.nih.gov/pubmed/35239514
http://dx.doi.org/10.1172/JCI150846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057613/
https://www.ncbi.nlm.nih.gov/pubmed/35239514
http://dx.doi.org/10.1172/JCI150846

Ejemplares similares